Regen BioPharma Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Regen BioPharma Inc. has filed its quarterly report (10-Q) for the period ending March 31, 2024.</b>

AI Summary

Regen BioPharma Inc (RGBPP) filed a Quarterly Report (10-Q) with the SEC on April 24, 2024. Regen BioPharma Inc. filed a 10-Q report for the period ending March 31, 2024. The company's fiscal year ends on September 30. The filing covers the second quarter of the fiscal year. The company's principal business address is in La Mesa, California. The filing was made as of April 24, 2024.

Why It Matters

For investors and stakeholders tracking Regen BioPharma Inc, this filing contains several important signals. This 10-Q filing provides an update on Regen BioPharma's financial performance and operational status for the most recent quarter. Investors and stakeholders can use this report to assess the company's progress, financial health, and potential risks.

Risk Assessment

Risk Level: — Regen BioPharma Inc shows moderate risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain immediate, significant financial or operational disclosures that would indicate high risk.

Analyst Insight

Review the detailed financial statements and any management discussion and analysis within the 10-Q to understand Regen BioPharma's current financial position and future outlook.

Key Numbers

• 2024-03-31 — Reporting Period End Date (The 10-Q filing is for the period ending on this date.)
• 2024-04-24 — Filing Date (The date the 10-Q report was filed with the SEC.)
• 0930 — Fiscal Year End (The company's fiscal year concludes on September 30.)

Key Players & Entities

• Regen BioPharma Inc. (company) — Filer of the 10-Q report.
• 2024-03-31 (date) — Period ending date for the 10-Q filing.
• 2024-04-24 (date) — Filing date of the 10-Q report.
• La Mesa, CA (location) — Location of the company's business and mailing address.

FAQ

Industry Context

Regen BioPharma Inc. operates in the pharmaceutical preparations industry, focusing on the development of biopharmaceutical products.

Regulatory Implications

The company is subject to standard SEC reporting requirements for public companies, including the filing of quarterly reports (10-Q).

What Investors Should Do

1. Analyze the financial statements for the quarter ending March 31, 2024.
2. Review any disclosures regarding the company's product development pipeline and clinical trials.
3. Assess the company's cash position and burn rate.

Key Dates

• 2024-03-31: Quarterly Period End — Marks the end of the reporting period for the 10-Q.
• 2024-04-24: Filing Date — The date the 10-Q was officially submitted to the SEC.

Year-Over-Year Comparison

This is a standard 10-Q filing, providing routine quarterly financial and operational updates.

Filing Documents

• rgbp033124form10q.htm (10-Q) — 1065KB
• ex31_1.htm (EX-31.1) — 9KB
• ex31_2.htm (EX-31.2) — 9KB
• ex32_1.htm (EX-32.1) — 4KB
• ex32_2.htm (EX-32.2) — 4KB
• 0001607062-24-000131.txt (&nbsp;) — 3751KB
• rgbp-20240331.xsd (EX-101.SCH) — 41KB
• rgbp-20240331_cal.xml (EX-101.CAL) — 43KB
• rgbp-20240331_def.xml (EX-101.DEF) — 111KB
• rgbp-20240331_lab.xml (EX-101.LAB) — 211KB
• rgbp-20240331_pre.xml (EX-101.PRE) — 187KB
• rgbp033124form10q_htm.xml (XML) — 453KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File No. 333-191725 REGEN BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Nevada 45-5192997 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4700 Spring Street , St 304 , La Mesa , California 91942 (Address of Principal Executive Offices) 619 722-5505 (Issuer's telephone number) None (Former name, address and fiscal year, if changed since last report) Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "non-accelerated Large accelerated filer Accelerated Smaller reporting company Emerging Growth Company APPLICABLE ONLY TO CORPORATE ISSUERS: As of March 31, 2024 Regen Biopharma, Inc. had 4,114,622 common shares outstanding. As of March 31, 2024 Regen Biopharma, Inc. had 409,551 shares of Series A Preferred Stock outstanding. As of March 31, 2024 Regen Biopharma, Inc. had 34 shares of Series AA Preferred Stock outstanding. As of March 31, 2024 Regen Biopharma, Inc. had 29,338 shares of Series M Preferred Stock outstanding. As of March 31, 2024 Regen Biopharma, Inc. had 15,007 shares of Series NC Preferred Stock outstanding. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No 1 PART I - FINANCIAL INFORMATION Item 1. - Financial Statements REGEN BIOPHARMA , INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of March 31, 2024 September 30, 2023 (unaudited) ASSETS CURRENT ASSETS Cash $ 78,115 $ 121,037 Accounts Receivable, Related Party 39,723 0 Note Receivable, Related Party 0 Prepaid Expenses 200 0 Prepaid Rent 5,000 10,000 Total Current Assets 123,037 131,037 Investment Securities, Related Party 17,733 222,580 Total Other Assets 17,733 222,580 Total Assets $ 140,770 $ 353,617 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable 29,798 29,674 Notes Payable 49,210 95,710 Accrued payroll taxes 4,241 4,241 Accrued Interest 342,416 342,588 Accrued Payroll 1,256,630 1,256,630 Other Accrued Expenses 41,423 41,423 Bank Overdraft 1,000 1,000 Due to Investor 20,000 20,000 Unearned Income 1,528,451 1,591,731 Unearned Income (Related Party) 0 15,126 Derivative Liability 1,400,000 1,400,000 Convertible Notes Payable Less unamortized discount 499,880 499,880 Convertible Notes Payable, Related Parties Less unamortized discount 0 10,000 Total Current Liabilities 5,173,049 5,308,003 Long Term Liabilities: Convertible Notes Payable, Related Parties Less unamortized discount Notes Payable 143,685 149,614 Total Long Term Liabilities 143,685 149,614 Total Liabilities 5,316,734 5,457,617 STOCKHOLDERS' EQUITY (DEFICIT) Common Stock ($ .0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,114,622 issued and outstanding as of March 31, 2024 and 3,506,366 shares issued and outstanding as of September 30, 2023. 412 352 Preferred Stock, 0.0001 par value, 800,000,000 authorized as of March 31, 2024 and September 30, 2023 respectively 40 40 Series A Preferred; 739,000,000 authorized as of September 30, 2023 and March 31, 2024; 409,551 outstanding as of March 31, 2024 and September 30, 2023 40 40 Series AA Preferred; $ 0.0001 par value 600,000 authorized and 34 and 34 outstanding as of March 31, 2024 and September 30,2023 respectively 0 0 Series M Preferred; $ 0.0001 par value 60,000,000 authorized and 29,338 outstanding as of September 30, 2023 and 60,000,000 authorized and 29,338 outstanding as of March 31, 2024 3 3 Series NC Preferred; $ 0.0001 par value 20,000 authorized and 15,007 outstanding as of September 30, 2023 and March 31, 2024 2 2 Ad

View Full Filing

View this 10-Q filing on SEC EDGAR